# A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07294508/  
OnCo record `nct07294508` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Pertuzumab in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 2/3 interventional study registered as NCT07294508 by Shanghai Henlius Biotech, with 706 participants planned, started 2026-02-27 and due to reach its primary completion in 2028-01-15. Interventions recorded: HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab and THP.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07294508
- Phase: 2/3
- Setting: An Open-Label, Randomized, Multicenter, Phase II/III Clinical Study to Evaluate HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With HLX87 (HER2 ADC) as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 706

## Sources

- ClinicalTrials.gov NCT07294508: https://clinicaltrials.gov/study/NCT07294508

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct07294508.json